IDH1 and astrocytoma (excluding glioblastoma): In follow‐up studies, more biomarkers that correlate to the prognosis of IDH‐mutant, Grade 4 astrocytomas, including tumor group‐specific genomic methylation profiles and copy number variations (CNV), should be considered and evaluated.